Pfizer says cancer therapy Braftovi improved survival in late-stage trial
Source: SeekingAlpha
2026-02-17 09:11:22 ET
More on Pfizer
- Pfizer: A Great Opportunity Post Earnings
- Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity
- Pfizer Inc. 2025 Q4 - Results - Earnings Call Presentation
- Changes to U.S. vaccine policy under RFK Jr. challenged in court
- RFK Jr. HHS shakeup continues as deputy secretary leaving post - report
Read the full article on Seeking Alpha
For further details see:
Pfizer says cancer therapy Braftovi improved survival in late-stage trial
Ono Pharmaceutical Co Ltd
NASDAQ: OPHLF
OPHLF Trading
0.0% G/L:
$16 Last:
625 Volume:
$16 Open:
